Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261


Rgenix is made possible through financing from investors including Novo A/S, Sofinnova Partners, Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.